Home Cart Sign in  
Chemical Structure| 218156-96-8 Chemical Structure| 218156-96-8

Structure of SRPIN340
CAS No.: 218156-96-8

Chemical Structure| 218156-96-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SRPIN340 is an inhibitor of serine/arginine-rich protein kinase SRPK1 with IC50 of 0.89 μM.

Synonyms: SRPK inhibitor

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SRPIN340

CAS No. :218156-96-8
Formula : C18H18F3N3O
M.W : 349.35
SMILES Code : O=C(NC1=CC(C(F)(F)F)=CC=C1N2CCCCC2)C3=CC=NC=C3
Synonyms :
SRPK inhibitor
MDL No. :MFCD00116244
InChI Key :DWFGGOFPIISJIT-UHFFFAOYSA-N
Pubchem ID :2797577

Safety of SRPIN340

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Related Pathways of SRPIN340

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293 cells 10, 20, 50 µM 12 hours SRPIN340 promotes degradation of SRp75 Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11329-33.
HeLa cells 10 µM 16 hours SRPIN340 showed minimal effect on SR protein phosphorylation at 10 μM concentration Cell Chem Biol. 2018 Apr 19;25(4):460-470.e6.
Vero cells 40 µM 20 hours SRPIN340 inhibits cytopathic effect of Sindbis virus Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11329-33.
Primary RPE cells 10 µM 24 hours SRPIN340 significantly reduced pro-angiogenic VEGF expression Invest Ophthalmol Vis Sci. 2013 Aug 27;54(8):5797-806.
ARPE-19 cells 10 µM 24 hours SRPIN340 significantly increased the expression of VEGF xxxb protein isoforms relative to total VEGF in ARPE-19 cells Invest Ophthalmol Vis Sci. 2013 Aug 27;54(8):5797-806.
PBLs from ENKTL patients 12.5 µM 24 hours SRPK1 inhibitors decreased cell activity and increased apoptosis BMC Cancer. 2022 Oct 27;22(1):1100.
YT cells 12.5 µM 24 hours SRPK1 inhibition significantly reduced YT cell viability and induced apoptosis BMC Cancer. 2022 Oct 27;22(1):1100.
92.1 1-10 µM 24-48 hours SRPIN340 reduced VEGF165 mRNA in a dose-dependent manner in all four cell lines tested. Furthermore, total VEGF protein was similarly reduced by SRPIN340 reaching significance at 10 μM in A375, Omm2.5 and 92.1 cells. Br J Cancer. 2014 Jul 29;111(3):477-85.
Mel270 1-10 µM 24-48 hours SRPIN340 reduced VEGF165 mRNA in a dose-dependent manner in all four cell lines tested. Furthermore, total VEGF protein was similarly reduced by SRPIN340 reaching significance at 10 μM in A375, Omm2.5 and 92.1 cells. Br J Cancer. 2014 Jul 29;111(3):477-85.
Omm2.5 1-10 µM 24-48 hours SRPIN340 reduced VEGF165 mRNA in a dose-dependent manner in all four cell lines tested. Furthermore, total VEGF protein was similarly reduced by SRPIN340 reaching significance at 10 μM in A375, Omm2.5 and 92.1 cells. Br J Cancer. 2014 Jul 29;111(3):477-85.
A375 1-10 µM 24-48 hours SRPIN340 reduced VEGF165 mRNA in a dose-dependent manner in all four cell lines tested. Furthermore, total VEGF protein was similarly reduced by SRPIN340 reaching significance at 10 μM in A375, Omm2.5 and 92.1 cells. Br J Cancer. 2014 Jul 29;111(3):477-85.
LNCaP-MYC prostate cancer cells 20 µM 4 days To evaluate the anti-proliferative effect of SRPIN340 on MYC-overexpressing cells, results showed SRPIN340 significantly inhibited cell proliferation. Mol Oncol. 2024 Oct;18(10):2510-2523.
22RV1 prostate cancer cells 20 µM 4 hours To assess the effect of SRPIN340 on nascent transcription, results showed SRPIN340 significantly upregulated transcription of long genes. Mol Oncol. 2024 Oct;18(10):2510-2523.
T24 cells 5–80 µM 48 hours SRPIN340 significantly prevented the nuclear translocation of SRPK1 and SRPK2 in 5-FU and cisplatin-treated T24 cells, thus diminishing the cytotoxic effects of the drug. Cells. 2021 Mar 30;10(4):759.
HeLa cells 5–80 µM 48 hours SRPIN340 significantly prevented the nuclear translocation of SRPK1 and SRPK2 in 5-FU and cisplatin-treated HeLa cells, thus diminishing the cytotoxic effects of the drug. Cells. 2021 Mar 30;10(4):759.
MDA PCa 2b 25 µM 48 hours Inhibition of SRSF2 activity enhances sensitivity of PI3Kδ inhibitors to PI3Kδ-S-expressing cells Cancers (Basel). 2023 Feb 20;15(4):1337.
Prostate cancer cells (22Rv1, LNCaP, MDA PCa 2b, HT-29, A549, MCF-7) 25 µM 48 hours To evaluate the inhibitory effect of SRPIN340 on the PIK3CD-S splice variant and its impact on the AKT/mTOR signaling pathway. Results showed that SRPIN340 treatment significantly reduced PIK3CD-S expression and inhibited the AKT/mTOR signaling pathway. Front Endocrinol (Lausanne). 2023 Aug 21;14:1190479.
Huh7 cells 30 µM 48 hours SRPIN340 significantly suppressed HCV core antigen secretion and intracellular core protein expression in HCV-JFH1-infected Huh7 cells. Antimicrob Agents Chemother. 2010 Aug;54(8):3179-86.
Huh7/Rep-Feo-2a cells 15.8 µM (EC50) 48 hours SRPIN340 suppressed HCV 2a subgenomic replicon expression in a dose-dependent manner with an EC50 of 15.8 µM. Antimicrob Agents Chemother. 2010 Aug;54(8):3179-86.
Huh7/Rep-Feo-1b cells 4.7 µM (EC50) 48 hours SRPIN340 suppressed HCV 1b subgenomic replicon expression in a dose-dependent manner with an EC50 of 4.7 µM. Antimicrob Agents Chemother. 2010 Aug;54(8):3179-86.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Subcutaneous xenograft model Subcutaneous injection 2 mg Daily for 27 days SRPIN340 significantly reduced tumour growth and decreased total VEGF expression in tumours, but did not affect anti-angiogenic VEGF xxxb isoforms. Additionally, SRPIN340 significantly reduced microvascular density (MVD). Br J Cancer. 2014 Jul 29;111(3):477-85.
Sprague Dawley rats 50/10 Oxygen Induced Retinopathy model Intraocular injection 25 ng Single injection SRPIN340 significantly reduced PRNV and decreased pro-angiogenic VEGF expression Invest Ophthalmol Vis Sci. 2013 Aug 27;54(8):5797-806.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.86mL

0.57mL

0.29mL

14.31mL

2.86mL

1.43mL

28.62mL

5.72mL

2.86mL

References

 

Historical Records

Categories